摘要
目的:观察二甲双胍和罗格列酮对2型糖尿病肾病治疗效果。方法:将80例主要表现为微量白蛋白尿的2型糖尿病肾病患者按随机数字表法分两组,每组40例,分别应用罗格列酮和二甲双胍治疗,观察治疗前后24 h尿蛋白定量、尿微量白蛋白、肾功能等指标的变化。结果:两组治疗后FPG、2 h PG、HbA1c均明显下降,且下降程度相似。治疗组的UAE、UAER、TG也下降,HDL-C升高(P<0.05),TC、LDL-C两组比较差异均无统计学意义(P>0.05)。治疗组显效12例,有效22例,无效6例,总有效率85%;对照组显效8例,有效18例,无效14例,总有效率65%。结论:罗格列酮治疗DN除了具有改善胰岛素抵抗、降低血糖作用外,还可显著减少尿蛋白排泄,轻度改善肾功能。
Objective：To observe the clinical effect of melbine and rosiglitazone on treating type 2 diabetic mellitus. Method：80 patients with type 2 diabetic mellitus were randomly divided into two groups. They were treated by rosiglitazone and melbine respectively. The Urine protein quantitation in 24 hours,microalbuminuria,renal function were compared. Result：The FPG,2 h PG and HbA1c declined obviously,with similar degrees. The UAE, UAER and TG declined too,HDL-C increased（P〈0.05）. There was no statistically significant in TC and LDL-C（P〉0.05）. In the treatment group, 12 cases were significantly effective,22 cases effective,6 cases were invalidity,the total effective rate was 85 percent. In the control group,8 cases were significantly effective,18 cases effective,14 cases were invalidity,the total effective rate was 65 percent. Conclusion：It can improve the insulin-resistance,reducing blood sugar levels,and it can significantly reduced urine protein and improve the renal function.
出处
《中国医学创新》
CAS
2013年第36期13-14,共2页
Medical Innovation of China
基金
江西省科技厅课题省级成果(2010zdso2600)
关键词
罗格列酮
二甲双胍
2型糖尿病
糖尿病肾病
Rosiglitazone
Melbine
Type 2 diabetic mellitus
Diabetic nephropathy
